Mark Messing

1.9k total citations · 1 hit paper
31 papers, 1.1k citations indexed

About

Mark Messing is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, Mark Messing has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Reproductive Medicine, 13 papers in Surgery and 11 papers in Obstetrics and Gynecology. Recurrent topics in Mark Messing's work include Ovarian cancer diagnosis and treatment (14 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Intraperitoneal and Appendiceal Malignancies (4 papers). Mark Messing is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Endometrial and Cervical Cancer Treatments (11 papers) and Intraperitoneal and Appendiceal Malignancies (4 papers). Mark Messing collaborates with scholars based in United States, Spain and Australia. Mark Messing's co-authors include Kenneth C. Hancock, Danny Rischin, Michael Friedländer, Joanne Lager, Matthew H. Taylor, Carol Aghajanian, Marcia S. Brose, Vicky Makker, Emmett V. Schmidt and Allen Lee Cohn and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of the New York Academy of Sciences.

In The Last Decade

Mark Messing

31 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Messing United States	13	478	420	306	261	225	31	1.1k
Chad A. Hamilton United States	11	500 1.0×	290 0.7×	504 1.6×	214 0.8×	117 0.5×	26	1.0k
P Maxwell United Kingdom	22	296 0.6×	451 1.1×	289 0.9×	431 1.7×	320 1.4×	40	1.5k
Joshua Z. Press Canada	17	410 0.9×	230 0.5×	417 1.4×	218 0.8×	183 0.8×	27	985
Rosanna Fontanelli Italy	24	685 1.4×	280 0.7×	694 2.3×	145 0.6×	412 1.8×	51	1.3k
Marjan Rouzbahman Canada	18	578 1.2×	254 0.6×	664 2.2×	180 0.7×	201 0.9×	49	1.3k
Robert E. Scully United States	19	921 1.9×	285 0.7×	648 2.1×	197 0.8×	386 1.7×	21	1.6k
Najmosama Nikrui United States	18	887 1.9×	347 0.8×	641 2.1×	336 1.3×	205 0.9×	33	1.6k
Fabio Cappuccini United States	17	271 0.6×	300 0.7×	225 0.7×	210 0.8×	147 0.7×	36	843
Golnar Rasty Canada	18	439 0.9×	258 0.6×	719 2.3×	164 0.6×	200 0.9×	30	1.1k
B. Frankendal Sweden	20	436 0.9×	166 0.4×	437 1.4×	140 0.5×	278 1.2×	50	998

Countries citing papers authored by Mark Messing

Since Specialization

Citations

This map shows the geographic impact of Mark Messing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Messing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Messing more than expected).

Fields of papers citing papers by Mark Messing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Messing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Messing. The network helps show where Mark Messing may publish in the future.

Co-authorship network of co-authors of Mark Messing

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Messing. A scholar is included among the top collaborators of Mark Messing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Messing. Mark Messing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Makker, Vicky, Carol Aghajanian, Allen Lee Cohn, et al.. (2023). A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. Journal of Clinical Oncology. 41(5). 974–979. 25 indexed citations

Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2021). 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111. Annals of Oncology. 32. S760–S760. 1 indexed citations

Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2020). Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 38(26). 2981–2992. 359 indexed citations breakdown →

Müller, Frank, Mark Messing, Jeanne F. Loring, et al.. (2010). A 3-dimensional extracellular matrix as a delivery system for the transplantation of glioma-targeting neural stem/progenitor cells. Neuro-Oncology. 12(7). 645–654. 18 indexed citations

Friedländer, Michael, Kenneth C. Hancock, Danny Rischin, et al.. (2010). A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology. 119(1). 32–37. 171 indexed citations

Juhila, Juuso, Markus Lassila, Mark Messing, et al.. (2010). -Catenin mediates adriamycin-induced albuminuria and podocyte injury in adult mouse kidneys. Nephrology Dialysis Transplantation. 25(8). 2437–2446. 58 indexed citations

Gordon, Alan N., Kenneth C. Hancock, Carolyn M. Matthews, et al.. (2002). Phase I Study of Alternating Doublets of Topotecan/Carboplatin and Paclitaxel/Carboplatin in Patients with Newly Diagnosed, Advanced Ovarian Cancer. Gynecologic Oncology. 85(1). 129–135. 11 indexed citations

Gordon, Anderley, Mark Doherty, Mark Messing, et al.. (1999). Phase I study of topotecan (T) with carboplatin (C) alternating with paclitaxel (P) via 3 hour infusion with carboplatin (C) in treatment of newly diagnosed ovarian cancer (OC). European Journal of Cancer. 35. S237–S237. 6 indexed citations

Ferris, Daron G., et al.. (1997). The Efficacy of Topical Benzocaine Gel in Providing Anesthesia Prior to Cervical Biopsy and Endocervical Curettage. Journal of Lower Genital Tract Disease. 1(4). 221–227. 1 indexed citations

10.

Gallup, Donald G., et al.. (1997). The cystometric evaluation of bladder function before and after radical hysterectomy. 3(1). 15–18. 1 indexed citations

11.

King, Laurel A., Takashi Okagaki, Donald G. Gallup, et al.. (1996). Mitotic Count, Nuclear Atypia, and Immunohistochemical Determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 Expression in Granulosa Cell Tumors of the Ovary: Mitotic Count and Ki-67 Are Indicators of Poor Prognosis. Gynecologic Oncology. 61(2). 227–232. 66 indexed citations

12.

Messing, Mark, et al.. (1995). Carcinoma of the vulva in young women. Obstetrics and Gynecology. 86(1). 51–54. 77 indexed citations

13.

Messing, Mark, et al.. (1995). Development of Murine (OC‐147) and Human (H‐106) Monoclonal Antibodies Reactive with a 53‐kDa Ovarian Tumor‐associated Antigen. Annals of the New York Academy of Sciences. 768(1). 264–268. 2 indexed citations

14.

Ferris, Daron G., Mark Messing, & John H. Crosby. (1995). Vaginal intraepithelial neoplasia III detected after hysterectomy for benign conditions.. PubMed. 40(1). 81–5. 3 indexed citations

15.

Westphal, Manfred, Wolfgang Hamel, H. -D. Herrmann, et al.. (1994). Epidermal Growth Factor Receptor Expression in Human Malignant Glioma: In Vitro and In Vivo Effects of Application of Monoclonal Antibodies to the Epidermal Growth Factor Receptor. Recent results in cancer research. 135. 171–184. 8 indexed citations

16.

Munkarah, Adnan, David M. Gershenson, Charles Levenback, et al.. (1994). Salvage Surgery for Chemorefractory Ovarian Germ Cell Tumors. Gynecologic Oncology. 55(2). 217–223. 35 indexed citations

17.

Messing, Mark, Mary S. Richardson, Michael T. Smith, Laurel A. King, & Donald G. Gallup. (1993). Metastatic Clear-Cell Hidradenocarcinoma of the Vulva. Gynecologic Oncology. 48(2). 264–268. 23 indexed citations

18.

Gallup, Donald G., Laurel A. King, Mark Messing, & O. Eduardo Talledo. (1993). Paraaortic lymph node sampling by means of an extraperitoneal approach with a supraumbilical transverse “sunrise” incision. American Journal of Obstetrics and Gynecology. 169(2). 307–312. 9 indexed citations

19.

Messing, Mark, David M. Gershenson, Michael B. Morris, et al.. (1992). Primary treatment failure in patients with malignant ovarian germ cell neoplasms. International Journal of Gynecological Cancer. 2(6). 295–300. 17 indexed citations

20.

Messing, Mark, F O Sottnek, James W. Biddle, et al.. (1983). Isolation of Haemophilus Species from the Genital Tract. Sexually Transmitted Diseases. 10(2). 56–61. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact